Tolga Tanguler Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

Tolga Tanguler is EVP, Chief Commercial Officer of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 28,011 shares of ALNY, which is worth approximately $6.77 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 471 shares (Common Stock) at a price of $244.82 per share, resulting in proceeds of $115,310. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28K

112.35% 3M change

180.47% 12M change

Total Value Held $6.77 Million

Tolga Tanguler Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Open market or private sale	$115,310 $244.82 p/Share	471 Reduced 1.65%	28,011 Common Stock
Mar 03 2025	BUY Grant, award, or other acquisition	-	14,137 Added 33.17%	28,482 Common Stock
Feb 28 2025	SELL Open market or private sale	$123,479 $240.7 p/Share	513 Reduced 3.45%	14,345 Common Stock
Feb 27 2025	BUY Exercise of conversion of derivative security	-	1,667 Added 10.09%	14,858 Common Stock
Nov 26 2024	SELL Open market or private sale	$367,764 $250.35 p/Share	1,469 Reduced 10.02%	13,191 Common Stock
Nov 25 2024	BUY Grant, award, or other acquisition	-	3,000 Added 16.99%	14,660 Common Stock
Jun 25 2024	SELL Open market or private sale	$368,219 $229.42 p/Share	1,605 Reduced 12.1%	11,660 Common Stock
Jun 24 2024	BUY Grant, award, or other acquisition	-	3,278 Added 19.82%	13,265 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	4,751 Added 32.24%	9,987 Common Stock
Feb 28 2024	SELL Open market or private sale	$78,331 $156.35 p/Share	501 Reduced 8.73%	5,236 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	-	1,667 Added 22.51%	5,737 Common Stock
Feb 16 2024	SELL Open market or private sale	$149,594 $148.26 p/Share	1,009 Reduced 19.87%	4,070 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	3,278 Added 39.22%	5,079 Common Stock
Apr 27 2023	SELL Open market or private sale	$287,760 $194.96 p/Share	1,476 Reduced 45.04%	1,801 Common Stock
Apr 26 2023	BUY Grant, award, or other acquisition	-	3,277 Added 50.0%	3,277 Common Stock
Feb 03 2023	SELL Open market or private sale	$790,978 $231.01 p/Share	3,424 Reduced 100.0%	0 Common Stock
Feb 02 2023	SELL Open market or private sale	$361,729 $225.94 p/Share	1,601 Reduced 31.86%	3,424 Common Stock
Feb 01 2023	BUY Exercise of conversion of derivative security	-	5,025 Added 50.0%	5,025 Common Stock
Aug 05 2022	SELL Open market or private sale	$404,376 $219.65 p/Share	1,841 Reduced 100.0%	0 Common Stock
Aug 04 2022	SELL Payment of exercise price or tax liability	$357,832 $200.13 p/Share	1,788 Reduced 49.27%	1,841 Common Stock
Aug 03 2022	SELL Open market or private sale	$368,340 $210.0 p/Share	1,754 Reduced 32.58%	3,629 Common Stock
Aug 03 2022	BUY Grant, award, or other acquisition	-	3,629 Added 40.27%	5,383 Common Stock
Jul 05 2022	SELL Open market or private sale	$263,100 $150.0 p/Share	1,754 Reduced 50.0%	1,754 Common Stock
Feb 02 2022	SELL Payment of exercise price or tax liability	$219,609 $144.67 p/Share	1,518 Reduced 30.2%	3,508 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	-	5,026 Added 50.0%	5,026 Common Stock

Also insider at

LXEO

Lexeo Therapeutics, Inc.

Tolga Tanguler

EVP, Chief Commercial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALNY shares.

Notify only if

Value

Insider Trading

Get notified when an Alnylam Pharmaceuticals, Inc. insider buys or sells ALNY shares.

Notify only if

Operation

Value

Type

News

Receive news related to ALNYLAM PHARMACEUTICALS, INC.

Track Activities on ALNY

Account